Suppr超能文献

他克莫司自微乳固体分散体的理化性质及药代动力学特征研究。

Self-micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization.

机构信息

Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Pharmaceutical Research and Technology Labs, Astellas Pharma Inc., Shizuoka, Japan.

出版信息

Biopharm Drug Dispos. 2023 Dec;44(6):387-395. doi: 10.1002/bdd.2373. Epub 2023 Aug 1.

Abstract

The present study was undertaken to develop a self-micellizing solid dispersion (SMSD) of tacrolimus (TAC) to improve the biopharmaceutical properties of TAC. An SMSD formulation of TAC (SMSD/TAC) and amorphous solid dispersion formulation of TAC (ASD/TAC) were prepared with Soluplus , an amphiphilic copolymer, and hydroxypropyl cellulose, respectively. Physicochemical properties were characterized in terms of morphology, crystallinity, storage stability, interaction of TAC with Soluplus , and micelle-forming potency; pharmacokinetic behavior was also evaluated in rats. Tacrolimus in both formulations was in an amorphous state. After storage at 40°C/75% relativity humidity for 4 weeks, there were no significant changes in the crystallinity of TAC between nonaged and aged SMSD/TAC, whereas slight recrystallization was observed in aged ASD/TAC. The results of circular dichroism (CD) and infrared spectroscopic analyses were indicative of the potent drug-polymer interaction in SMSD/TAC, possibly leading to the prevention of recrystallization. Compared with other TAC samples, SMSD/TAC exhibited significant improvement in the dissolution behavior of TAC through the immediate formation of fine micelles. After the oral administration of TAC samples (10 mg TAC/kg) to rats, there was marked enhancement in systemic exposure to TAC with both formulations; in particular, SMSD/TAC achieved an increase in bioavailability ca. 20-fold higher than crystalline TAC. The SMSD approach might provide an effective dosage form for TAC with enhanced physicochemical stability and oral absorption.

摘要

本研究旨在开发他克莫司(TAC)自微乳分散体(SMSD)以改善 TAC 的生物药剂学性质。采用两亲性共聚物 Soluplus 和羟丙纤维素分别制备 TAC 的 SMSD 制剂(SMSD/TAC)和无定形固体分散体制剂(ASD/TAC)。从形态、结晶度、储存稳定性、TAC 与 Soluplus 的相互作用以及胶束形成能力等方面对物理化学性质进行了表征;还在大鼠中评价了其药代动力学行为。两种制剂中的他克莫司均处于无定形态。在 40°C/75%相对湿度下储存 4 周后,非老化和老化的 SMSD/TAC 之间 TAC 的结晶度没有明显变化,而 ASD/TAC 中观察到轻微的再结晶。圆二色性(CD)和红外光谱分析结果表明,SMSD/TAC 中存在强烈的药物-聚合物相互作用,可能导致再结晶的抑制。与其他 TAC 样品相比,SMSD/TAC 通过立即形成细胶束,显著改善了 TAC 的溶解行为。大鼠口服 TAC 样品(10mg TAC/kg)后,两种制剂均显著提高了 TAC 的全身暴露;特别是,SMSD/TAC 的生物利用度提高了约 20 倍,高于结晶 TAC。SMSD 方法可为 TAC 提供一种有效的剂型,具有增强的物理化学稳定性和口服吸收性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验